Integrative single-cell, spatial, and bulk transcriptomics reveal an FMR1–FTO axis linked to the immune-excluded phenotype in gastric cancer
Open Access
- 9 March 2026
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1713267
Abstract
Background: Immune exclusion is a major barrier to immune checkpoint inhibitor (ICI) efficacy in gastric cancer, yet the spatial mechanisms by which m 6 A regulators drive this phenotype remain unclear. Methods: We integrated single-cell RNA-seq, spatial transcriptomics, and functional assays to map the gastric cancer microenvironment and derived an m 6 A regulator score to quantify the spatial coupling between m 6 A patterns and immune exclusion. Results: CAFs emerged as a central hub that excluded T cells via collagen–integrin interactions and MIF signaling, forming a CAF-defined collagen barrier that impeded CD8 + T-cell entry into the tumor core. In immune-excluded samples, m 6 A regulator scores were selectively elevated in tumor nests compared with surrounding stroma. Across five bulk transcriptomic datasets, this phenotype was associated with reduced predicted ICI responsiveness, activation of chemotherapy resistance programs, and poor survival. Mechanistically, FTO was highly expressed in the immune-excluded phenotype and correlated with stromal activation and T-cell exclusion. Serial immunohistochemistry and multiplex immunofluorescence revealed high FMR1 protein expression in immune-excluded tumors, with CD8 + T cells largely confined to the stroma. Cycloheximide (CHX) chase and MG132 treatment showed that FMR1 depletion reduced FTO protein abundance and accelerated FTO turnover in an MG132-sensitive manner, consistent with a post-translational regulatory relationship. Conclusions: Collectively, our data support an FMR1–FTO module associated with the immune-excluded phenotype and nominate this axis as a potential vulnerability for disrupting stromal immune barriers. The FMR1–FTO axis may represent a candidate target for strategies aimed at relieving immune exclusion and improving immunotherapy sensitivity.Keywords
This publication has 47 references indexed in Scilit:
- Gastric cancerThe Lancet, 2025
- Co-Immunoprecipitation (Co-Ip) in Mammalian Cells2023
- First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trialThe Lancet, 2021
- Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability–High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical TrialsJAMA Oncology, 2021
- RNA N6-methyladenosine demethylase FTO regulates PD-L1 expression in colon cancer cellsBiochemical and Biophysical Research Communications, 2020
- Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune EvasionCancer Cell, 2020
- Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trialThe Lancet, 2018
- Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2017
- The m 6 A Methyltransferase METTL3 Promotes Translation in Human Cancer CellsMolecular Cell, 2016
- GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputersSoftwareX, 2015